(NASDAQ: SCYX) Scynexis's forecast annual revenue growth rate of -9.72% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Scynexis's revenue in 2026 is $20,344,000.On average, 5 Wall Street analysts forecast SCYX's revenue for 2026 to be $140,295,690, with the lowest SCYX revenue forecast at $78,165,195, and the highest SCYX revenue forecast at $205,041,436. On average, 5 Wall Street analysts forecast SCYX's revenue for 2027 to be $784,972,657, with the lowest SCYX revenue forecast at $152,053,200, and the highest SCYX revenue forecast at $1,453,164,643.
In 2028, SCYX is forecast to generate $1,140,955,095 in revenue, with the lowest revenue forecast at $508,750,622 and the highest revenue forecast at $1,728,910,022.